SRR8613792
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.530
- APICAL_JUNCTION+0.420
- UV_RESPONSE_DN+0.420
- HEDGEHOG_SIGNALING+0.380
- HYPOXIA+0.350
- INTERFERON_ALPHA_RESPONSE+0.350
- MYOGENESIS+0.350
- COAGULATION+0.320
- MITOTIC_SPINDLE+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.570
- MYC_TARGETS_V2-0.440
- MYC_TARGETS_V1-0.400
- FATTY_ACID_METABOLISM-0.380
- ADIPOGENESIS-0.350
- MTORC1_SIGNALING-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.260
- UV_RESPONSE_UP-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- ALLOGRAFT_REJECTION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20020022.TNBC | — | D | 0.852 |
| 2 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.849 |
| 3 | e72bd7b6-c350-4f96-a633-8bf86079f57c | — | — | 0.814 |
| 4 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.799 |
| 5 | SRR10900585 | — | — | 0.797 |
| 6 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.796 |
| 7 | ERR2208918 | — | — | 0.792 |
| 8 | SRR5088818 | — | — | 0.791 |
| 9 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.791 |
| 10 | 20030032.TNBC | — | D | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |